HR and breast cancer: Among the three drugs, palbociclib and abemaciclib have been approved for clinical use in Japan, with palbociclib receiving its first regulatory approval for unresectable or recurrent breast cancer in 2017 and abemaciclib receiving approval 1 year later for advanced HR+, HER2− breast cancer [18].